■ CLEA Japan, Inc. and Physiogenex S.A.S. collaboration.

CLEA Japan has signed a partnership with Physiogenex S. A. S., a leading preclinical contract research organization specializing in metabolic diseases and complications. Under this agreement, CLEA Japan, Inc. will represent Physiogenex to do marketing service to Japanese biopharmaceutical market.

■ What is Physiogenex

Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications.

It offers in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. It focuses on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis) and cardiovascular complications.

■ Service Condition (Agreement, Warranty, Indemnification, and etc.)

The below materials are example for the typical Physiogenex service conditions. Please refer them to confirm how the services are executed. (The actual conditions are changed depend on your orders.)

- Research Agreement (Template)
- Warranty and indemnification (Template)

■ Inquiry

From Japan: Please ask us from below (English/Japanese)


From countries other than Japan: You can contact Physiogenex directly.

■ Study Sample

Please refer below materials as a sample of the research services. Physiogenex can execute the research with your candidate compounds.

Title:
Unilateral Nephrectomy and Salt Supplementation in Spontaniously Diabetic Torii Fatty Rat Expedite Renal Complications and Glomerular Filtration Rate Decline within 10 Weeks

>Click below

Conclusion:

• Unilateral nephrectomy and salt supplementation in SDT fatty rat expedite renal complications resulting in a >50% GFR decline in only 10 weeks.
• The SDT fatty rat therefore represents a robust model to evaluate drugs targeting diabetic nephropathy.
• Anti-diabetic SGLT2 inhibitor dapagliflozin and anti-hypertensive ACE inhibitor ramipril are currently under evaluation.
• Presentation date - New York Academy of Sciences (Sep. 8, 2016)

Title:
Dapagliflozin Improves Glycemic Control, Hypertension and is Neutral on Severe Renal Impairment in Uni-nephrectomized SDT fatty rat, a 10-week Model of Advanced Renal Complications and Glomeurular Filtratin Rate Decline.

>Click below

Conclusion:

• Unilateral nephrectomy and salt supplementation in SDT fatty rat expedite renal complications resulting in a >50% GFR decline in only 10 weeks.
• Our data suggest that SGLT2i with DAPA has no detrimental effect in uni-nephrectomized SDT fatty rat with advanced renal complications and >50% GFR decline.
• Presentation date - Kidney Week (Nov. 18, 2016)

Title:
10-week, but not 7-week, Dapagliflozin treatment improves sever renal impairment in Uni-Nephrectomized SDT fatty rat, a 10-week model of advanced renal complications and Glomerular filtration rate decline.

>Click below

Conclusion: Conclusion:

• Dapagliflozin for 10 weeks, but not 7 weeks, significantly prevents advanced renal complications in Unx SDT fatty rats.
• Long-term SGLT2i may be beneficial against kidney complications in the context of type 2 diabetesPresentation date – ISN (Apr. 23, 2017) EDA-EDTA (Jun. 5, 2017) 

Title:
Dapagliflozin Alone or Combined with Ramipril Improves Hyperglycemia, Hypertension, and Prevents Kidney Complications and GFR Decline in the Nephrectomized SDT Fatty Rat Model of Diabetic Nephropathy.

>Click below

Conclusion:

• In the 10-week Unx SDT fatty rat under 0.3% salt, DAPA alone prevents kidney complications, while the combination with RAMI adds benefits by better delaying GFR decline.
• Our data suggest that SGLT2i/ACEi combination prevents progression to ESRD.
• Presentation date Kidney Week (Nov. 3, 2017) Keystone Symposia Conference (Feb. 26, 2018) ISN Frontier (Mar. 26, 2018)

Title:
Unilateral nephrectomy and salt loading differentially alter glomerular filtration rate in the hypertensive, obese, type 2 diabetic SDT fatty rat model of diabetic nephropathy

>Click below

Conclusion:

• In the SDT fatty rat, Unx and salt loading have limited effect on diabetic state, while it favors induction of dyslipidemia and differentially alter GFR.
• Depending on the experimental setting, this rat model should be helpful to evaluate the effects of drugs on hyperfiltration and GFR decline for the treatment of DN.
• Presentation date - Kidney Week (Oct. 27, 2018)